NZ569486A - Lantibiotic biosynthetic gene clusters from A.garbadinensis and A.liguriae - Google Patents

Lantibiotic biosynthetic gene clusters from A.garbadinensis and A.liguriae

Info

Publication number
NZ569486A
NZ569486A NZ569486A NZ56948607A NZ569486A NZ 569486 A NZ569486 A NZ 569486A NZ 569486 A NZ569486 A NZ 569486A NZ 56948607 A NZ56948607 A NZ 56948607A NZ 569486 A NZ569486 A NZ 569486A
Authority
NZ
New Zealand
Prior art keywords
seq
variant
sequence
nucleic acid
encoding
Prior art date
Application number
NZ569486A
Other languages
English (en)
Inventor
Stephen Boakes
Bargallo Jesus Cortes
Michael John Dawson
Original Assignee
Novacta Biosystems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novacta Biosystems Ltd filed Critical Novacta Biosystems Ltd
Publication of NZ569486A publication Critical patent/NZ569486A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/365Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinoplanes (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/045Actinoplanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NZ569486A 2006-01-17 2007-01-17 Lantibiotic biosynthetic gene clusters from A.garbadinensis and A.liguriae NZ569486A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0600928.6A GB0600928D0 (en) 2006-01-17 2006-01-17 Improvements relating to lantibiotics
PCT/GB2007/000138 WO2007083112A2 (en) 2006-01-17 2007-01-17 Lantibiotic biosynthetic gene clusters from a. garbadinensis and a. liguriae

Publications (1)

Publication Number Publication Date
NZ569486A true NZ569486A (en) 2011-07-29

Family

ID=35998187

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ569486A NZ569486A (en) 2006-01-17 2007-01-17 Lantibiotic biosynthetic gene clusters from A.garbadinensis and A.liguriae

Country Status (20)

Country Link
US (3) US7989416B2 (https=)
EP (2) EP2189472A1 (https=)
JP (1) JP5219837B2 (https=)
KR (1) KR101573536B1 (https=)
CN (1) CN101389641B (https=)
AT (1) ATE534659T1 (https=)
AU (1) AU2007206769B2 (https=)
BR (1) BRPI0706525A2 (https=)
CA (1) CA2637315A1 (https=)
CY (1) CY1112559T1 (https=)
DK (1) DK1979375T3 (https=)
ES (1) ES2378090T3 (https=)
GB (1) GB0600928D0 (https=)
IL (1) IL192446A0 (https=)
MX (1) MX2008009047A (https=)
NZ (1) NZ569486A (https=)
PL (1) PL1979375T3 (https=)
PT (1) PT1979375E (https=)
SI (1) SI1979375T1 (https=)
WO (1) WO2007083112A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
GB0714030D0 (en) * 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
GB0714029D0 (en) * 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
SI2387580T1 (sl) * 2009-01-14 2014-11-28 Novacta Biosystems Limited Deoksiaktagardinski derivati
MX2011008043A (es) * 2009-02-04 2011-08-17 Novacta Biosystems Ltd Derivados de actagardina.
JP5852966B2 (ja) * 2010-02-02 2016-02-03 ノヴァクタ バイオシステムズ リミティッド ランチビオティックの塩
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
US20130171252A1 (en) 2010-07-14 2013-07-04 Novacta Biosystems Limited Formulation Comprising a Type B Lantibiotic
GB201013509D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013508D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013507D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013513D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
EP2925342A4 (en) 2012-11-30 2016-07-06 Naicons Srl NOVEL LANTIBIOTIC DERIVATIVES AND PREPARATION METHOD THEREOF
CN103483433B (zh) * 2013-09-10 2015-05-27 中国科学院微生物研究所 一种新型高效的羊毛硫细菌素cerecidin及其应用
CN106188253B (zh) * 2016-08-26 2020-08-18 上海交通大学 抗菌肽Lexapeptide及其制备方法和用途
CN113777306A (zh) * 2020-06-09 2021-12-10 首都医科大学附属北京世纪坛医院 尿液果糖二磷酸醛缩酶b及其多肽片段在烧伤中的应用
CN115637247B (zh) * 2021-07-20 2026-02-24 中国科学院微生物研究所 生物氧化脱硫的盐单胞菌工程菌株及其全细胞催化脱硫方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB8507528D0 (en) 1985-03-22 1985-05-01 Lepetit Spa Basis monocarboxyamide derivatives
US5304540A (en) 1988-06-22 1994-04-19 Applied Microbiology, Inc. Pharmaceutical bacteriocin compositions and methods for using the same
IN167138B (https=) 1988-08-17 1990-09-01 Hoechst India
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
IT1260505B (it) 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
IL107887A (en) 1992-12-08 2003-07-06 Ambi Inc Stabilized lanthionine containing bacteriocin compositions
US5512269A (en) 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
EP0700998B1 (en) 1994-09-12 2003-11-26 Aventis Pharma Deutschland GmbH Recombinant mersacidin and a method for production
CN1138560C (zh) 1995-06-23 2004-02-18 Ambi股份有限公司 控制对抗生素耐药的革兰氏阳性细菌的方法和治疗感染的方法
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US5958873A (en) 1997-06-09 1999-09-28 University Of Cincinnati Oral formulation for treatment of bacteria-induced diseases of the colon
US5985823A (en) 1997-06-09 1999-11-16 Ambi Inc. Method for the treatment of diarrheal disease and for eliminating particular bacterial populations from the colon
DE19745583A1 (de) * 1997-10-15 1999-04-22 Hoechst Marion Roussel De Gmbh Neues Lantibiotikum verwandt mit Actagardine, Verfahren zur Herstellung und Verwendung derselben
US6569830B1 (en) 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
ATE273695T1 (de) 2000-06-28 2004-09-15 Smithkline Beecham Plc Nassvermahlung
GB0110432D0 (en) * 2001-04-27 2001-06-20 Plant Bioscience Ltd Lantibiotic production
WO2002103010A1 (en) 2001-06-14 2002-12-27 Plant Bioscience Limited Methods and materials for targeted gene disruption in actinomycete bacteria
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
JP2006502713A (ja) 2002-10-10 2006-01-26 モリケム メディシンズ, インコーポレイテッド デュラマイシンをコードする核酸
ES2281808T3 (es) 2003-07-18 2007-10-01 Vicuron Pharmaceuticals, Inc. Antibiotico 107891, sus factores a1 y a2, composiciones y sales farmaceuticamente aceptables y uso del mismo.
US7351687B2 (en) 2003-07-18 2008-04-01 Vicuron Pharmaceuticals, Inc. Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
US20050271650A1 (en) * 2004-02-17 2005-12-08 Cellmatrix, Inc. Method and composition for angiogenesis inhibition
GB0406870D0 (en) 2004-03-26 2004-04-28 Novacta Biosystems Ltd Improvements relating to the production of lantibiotics
JP2009509519A (ja) 2005-09-27 2009-03-12 ノヴァクタ バイオシステムズ リミティッド ランチビオティックメルサシジンの変種およびそれらの使用
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
KR20120038021A (ko) 2006-10-27 2012-04-20 화이자 프로덕츠 인코포레이티드 하이드록시프로필 메틸 셀룰로스 경질 캡슐 및 이의 제조 방법
CA2690267A1 (en) 2007-06-12 2008-12-18 The University Of British Columbia Small cationic antimicrobial peptides
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
WO2010058238A1 (en) 2008-11-24 2010-05-27 Sentinella Pharmaceuticals, Inc. ("Sentinella") Lantibiotic carboxyamide derivatives with enhanced antibacterial activity
SI2387580T1 (sl) 2009-01-14 2014-11-28 Novacta Biosystems Limited Deoksiaktagardinski derivati
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
MX2011008043A (es) 2009-02-04 2011-08-17 Novacta Biosystems Ltd Derivados de actagardina.
EP2216937A1 (en) 2009-02-10 2010-08-11 Alcatel Lucent Alarm notification between customer premises equipment and a remote management server

Also Published As

Publication number Publication date
MX2008009047A (es) 2008-12-18
JP5219837B2 (ja) 2013-06-26
AU2007206769B2 (en) 2013-06-20
CN101389641B (zh) 2013-06-05
KR101573536B1 (ko) 2015-12-11
CA2637315A1 (en) 2007-07-26
DK1979375T3 (da) 2012-03-19
WO2007083112A3 (en) 2008-05-08
EP1979375B1 (en) 2011-11-23
US7989416B2 (en) 2011-08-02
USRE45003E1 (en) 2014-07-08
JP2009523777A (ja) 2009-06-25
IL192446A0 (en) 2008-12-29
WO2007083112A2 (en) 2007-07-26
PL1979375T3 (pl) 2012-04-30
AU2007206769A1 (en) 2007-07-26
EP1979375A2 (en) 2008-10-15
GB0600928D0 (en) 2006-02-22
US20100048459A1 (en) 2010-02-25
EP1979375B9 (en) 2012-05-09
EP2189472A1 (en) 2010-05-26
PT1979375E (pt) 2012-03-06
CN101389641A (zh) 2009-03-18
ES2378090T3 (es) 2012-04-04
CY1112559T1 (el) 2016-02-10
US20110306091A1 (en) 2011-12-15
BRPI0706525A2 (pt) 2011-03-29
US8465947B2 (en) 2013-06-18
KR20080086517A (ko) 2008-09-25
ATE534659T1 (de) 2011-12-15
SI1979375T1 (sl) 2012-03-30

Similar Documents

Publication Publication Date Title
AU2007206769B2 (en) Lantibiotic biosynthetic gene clusters from A. garbadinensis and A. liguriae
AU2008285655B2 (en) Thiopeptide precursor protein, gene encoding it and uses thereof
JP2010535492A (ja) ランチビオティック107891の生合成のための遺伝子およびタンパク質
EP1413626A1 (en) Genes and proteins for the biosynthesis of the glycopeptide antibiotic A40926
JP7086984B2 (ja) Streptomyces fungicidicusの遺伝子組換え株におけるエンデュラシジンの産生を増強するための組成物及び方法
EP2327789A1 (en) Novel compound signamycin, method for production thereof, and use thereof
RU2773311C2 (ru) Модифицированные изоляты streptomyces fungicidicus и их применение
KR20120122500A (ko) 아글루코반코마이신을 생산하는 미생물
Spohn Exploiting gene regulation as an approach to identify, analyze and utilize the biosynthetic pathways of the glycopeptide ristomycin A and the zincophore [S, S]-EDDS in Amycolatopsis japonicum
Zhang et al. Identification and characterization of the anti-MRSA WAP-8294A2 biosynthetic gene cluster from Lysobacter enzymogenes OH11
Bell Analysis and manipulation of “actagardine” gene clusters from Actinoplanes
WO2006111743A2 (en) Identifying lantibiotic gene clusters and novel lantibiotic genes
Recktenwald et al. 10 Precursor-Directed Biosynthesis for the Generation of Novel Glycopetides
CN107641146A (zh) 高产盐屋霉素及其类似物的产生菌、盐屋霉素及其类似物的制法及其用途

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 JAN 2017 BY HENRY HUGHES

Effective date: 20131209

S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended
S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended
LAPS Patent lapsed